Clinical Trials

April 13, 2012

An open-label study to explore the impact of inhaled trepostinil sodium on ventilation perfusion matching when used for treatment of group 1 pulmonary arterial hypertension in patients with concomitant chronic obstructive pulmonary disease (COPD)

  • Start Date: 11/2011
  • End Date: 03/2013
  • Design: Open label
  • Age range (years): from 18 to 80
  • Type of PH
    • PH with lung involvement (Group 3)
  • Study Duration for individual patient: 16 weeks
  • Contact: Minal Patel at
  • Listing on


FacebookGoogle +TwitterLinkedInPinterestInstagramYouTubeBloggerFeedsPHAware Download our App

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.® | © 2015 Pulmonary Hypertension Association. All Rights Reserved.


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.